{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:08:11Z","timestamp":1792382891247,"version":"4.4.0"},"reference-count":173,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Fragility fractures are a major complication in chronic kidney disease (CKD), yet therapeutic strategies for their prevention remain highly controversial. The unique pathophysiology of CKD\u2013mineral and bone disorder (CKD-MBD), coupled with the paucity of dedicated clinical trials, create substantial uncertainty regarding the efficacy and safety of medical interventions established in the general osteoporosis population. This review summarizes the available evidence regarding fracture risk and bone mineral density including pragmatic clinical guidance for the use of calcium, vitamin D, phosphate binders, calcimimetics, bisphosphonates, denosumab, romosozumab, and teriparatide in patients with advanced non-dialysis CKD, on dialysis, and after kidney transplantation. For calcium, the conflicting balance between skeletal needs and risk of vascular calcification in the setting of declining kidney function and limited evidence for fracture prevention is outlined. For vitamin D, the gap between its widespread clinical use and the inconsistent data on fracture prevention is analyzed including a discussion of target levels in progressive kidney dysfunction. For phosphate binders, the evidence for fracture prevention, showing benefits in dialysis populations, is summarized together with a synthesis of data on potential risks of calcium-based agents. For calcimimetics, the available evidence on their role in fracture prevention, PTH, and calcium control is reviewed. For bisphosphonates, the unresolved question of benefit versus harm in advanced CKD stages are discussed and the evidence regarding efficacy and safety for various clinical settings is disentangled. For denosumab, the current data on fracture prevention is presented with emphasis on its renal-independent pharmacokinetics and strategies to mitigate hypocalcemia and rebound fracture risk. For romosozumab, the promising effects on bone health are reviewed alongside an analysis of cardiovascular safety data. For teriparatide, the limited evidence in patients with low bone turnover disease is evaluated. The review navigates the available evidence and unresolved controversies across therapeutic options, and provides pragmatic guidance to support individualized clinical decision-making.<\/jats:p>","DOI":"10.3390\/jcm14228145","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:55:31Z","timestamp":1763556931000},"page":"8145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease\u2014Summary of the Evidence and Pragmatic Clinical Guidance"],"prefix":"10.3390","volume":"14","author":[{"given":"Simeon","family":"Schietzel","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","article-title":"Chronic kidney disease-mineral and bone disorder: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","article-title":"Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy","volume":"79","author":"Behets","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1681\/ASN.2017050584","article-title":"Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy","volume":"29","author":"Salam","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ki.1993.323","article-title":"Aplastic osteodystrophy without aluminum: The role of \"suppressed\" parathyroid function","volume":"44","author":"Hercz","year":"1993","journal-title":"Kidney Int."},{"key":"ref_8","unstructured":"National Health Service (NHS) (2025, October 25). Calcium [Internet]. NHS; 2020. Available online: https:\/\/www.nhs.uk\/conditions\/vitamins-and-minerals\/calcium\/."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"German Nutrition Society (2013). New reference values for calcium. Ann. Nutr. Metab., 63, 186\u2013192.","DOI":"10.1159\/000354482"},{"key":"ref_10","unstructured":"Ross, A.C., Taylor, C.L., Yaktine, A.L., and Del Valle, H.B. (2011). The National Academies Collection: Reports funded by National Institutes of Health. Dietary Reference Intakes for Calcium and Vitamin D, National Academies Press. Copyright \u00a9 2011, National Academy of Sciences: Washington, DC, USA."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch. Osteoporos."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"w20352","DOI":"10.4414\/smw.2020.20352","article-title":"2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)","volume":"150","author":"Ferrari","year":"2020","journal-title":"Swiss Med. Wkly"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00393-024-01495-x","article-title":"Update on the DVO Guideline 2023 \u201cProphylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50\u201d-What\u2019s new for rheumatology?","volume":"83","author":"Pfeil","year":"2024","journal-title":"Z. fur Rheumatol."},{"key":"ref_14","unstructured":"Bone Health and Osteoporosis Foundation (BHOF) (2025, October 25). Get the Facts on Calcium and Vitamin D [Internet]. BHOF. Available online: https:\/\/www.bonehealthandosteoporosis.org\/patients\/treatment\/calciumvitamin-d\/get-the-facts-on-calcium-and-vitamin-d\/?utm_source=chatgpt.com."},{"key":"ref_15","unstructured":"International Osteoporossis Foundation (IOF) (2025, October 25). Prevention [Internet]. IOF. Available online: https:\/\/www.osteoporosis.foundation\/health-professionals\/prevention\/nutrition\/calcium."},{"key":"ref_16","unstructured":"Osteoporosis Canada (OC) (2025, October 25). Calcium [Internet]. OC. Available online: https:\/\/osteoporosis.ca\/calcium\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 UPDATE","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.5694\/mja2.52637","article-title":"2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age","volume":"222","author":"Wong","year":"2025","journal-title":"Med. J. Aust."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMra1700312","article-title":"Nutritional Management of Chronic Kidney Disease","volume":"377","author":"Fouque","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"Cd006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jbmr\/zjae021","article-title":"Risk factors for hip and vertebral fractures in chronic kidney disease: The CRIC study","volume":"39","author":"Hsu","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zhang, Z.X., Fu, C.S., Ye, Z.B., Jin, H.M., and Yang, X.H. (2025). Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: A comprehensive meta-analysis. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-03992-w"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of Treating Hyperphosphatemia with Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/IJNRD.S90791","article-title":"Effects of lanthanum carbonate versus calcium carbonate on vascular stiffness and bone mineral metabolism in hemodialysis patients with type 2 diabetes mellitus: A randomized controlled trial","volume":"8","author":"Wada","year":"2015","journal-title":"Int. J. Nephrol. Renovasc Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology"},{"key":"ref_27","first-page":"130","article-title":"Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: A randomized double-blind placebo-controlled study","volume":"20","author":"Rudnicki","year":"1994","journal-title":"Miner. Electrolyte Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10157-024-02493-8","article-title":"Calcium-based phosphate binders and bone mineral density in patients undergoing hemodialysis: A retrospective cohort study","volume":"28","author":"Kato","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hashimoto, H., Shikuma, S., Mandai, S., Adachi, S., and Uchida, S. (2021). Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-81287-4"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"(2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Siracusa, C., Carabetta, N., Morano, M.B., Manica, M., Strangio, A., Sabatino, J., Leo, I., Castagna, A., Cianflone, E., and Torella, D. (2024). Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252313096"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","article-title":"Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?","volume":"39","author":"Raggi","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ndt\/gfad185","article-title":"Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statement","volume":"39","author":"Evenepoel","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study","volume":"30","author":"Dionisi","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Dunlop, E., Pham, N.M., Van Hoang, D., Mazahery, H., Neo, B., Shrapnel, J., Kalmpourtzidou, A., Chai, K.E.K., Ng, L., and Black, L.J. (2025). A systematic review and meta-analysis of circulating 25-hydroxyvitamin D concentration and vitamin D status worldwide. J. Public Health, fdaf080.","DOI":"10.1093\/pubmed\/fdaf080"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Niculescu, D.A., Deacu, L.G., Caragheorgheopol, A., Popescu, N., Ghemigian, A., Procopiuc, C., Rosca, R., and Poiana, C. (2021). Combined Effects of Vitamin D Status, Renal Function and Age on Serum Parathyroid Hormone Levels. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.657991"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2023.04.003","article-title":"Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis","volume":"82","author":"Yeung","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e10611","DOI":"10.1002\/jbm4.10611","article-title":"Vitamin D Analogues and Fracture Risk in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"6","author":"Khelifi","year":"2022","journal-title":"JBMR Plus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9998891","DOI":"10.1155\/2022\/9998891","article-title":"Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial","volume":"2022","author":"Young","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00198-019-04902-1","article-title":"Fracture status in middle-aged individuals with early CKD: Cross-sectional analysis of the CARTaGENE survey","volume":"30","author":"Desbiens","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5414\/CN107180","article-title":"The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease","volume":"77","author":"Bosworth","year":"2012","journal-title":"Clin. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jbmr.4913","article-title":"Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS","volume":"38","author":"Komaba","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial","volume":"26","author":"Moe","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000452680","article-title":"2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial","volume":"45","author":"Thadhani","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_50","first-page":"185","article-title":"Controlled trial of calcitriol in hemodialysis patients","volume":"26","author":"Baker","year":"1986","journal-title":"Clin. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/jama.2018.17749","article-title":"Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial","volume":"320","author":"Shoji","year":"2018","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.ajkd.2021.08.022","article-title":"Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial","volume":"79","author":"Brimble","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_53","first-page":"793","article-title":"The Effect of 6 Month Alphacalcidol Treatment or Nutrition Education on the Nutrient Intakes, Bone Mineral Density and Bone Markers in Continuous Ambulatory Peritoneal Dialysis Patients","volume":"11","year":"2006","journal-title":"Korean J. Community Nutr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/ndt\/gfw222","article-title":"Symptomatic fracture risk in the renal replacement therapy population","volume":"32","author":"Dey","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00774-019-01041-9","article-title":"Bone fracture risk factors in prevalent hemodialysis patients","volume":"38","author":"Matias","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/jbmr.4440","article-title":"Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study","volume":"36","author":"Fusaro","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/jbmr.4621","article-title":"Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry","volume":"37","author":"Murashima","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s11255-018-1958-y","article-title":"Predictors of bone fractures in a single-centre cohort of hemodialysis patients: A 2-year follow-up study","volume":"50","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ajt.2022.12.007","article-title":"Nonskeletal and skeletal effects of high doses versus low doses of vitamin D(3) in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial","volume":"23","author":"Courbebaisse","year":"2023","journal-title":"Am. J. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jbmr.3094","article-title":"Serum Phosphate Is Associated With Fracture Risk: The Rotterdam Study and MrOS","volume":"32","author":"Koek","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107476","DOI":"10.1016\/j.jdiacomp.2019.107476","article-title":"FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease","volume":"34","author":"Ribeiro","year":"2020","journal-title":"J. Diabetes Complications"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e2502","DOI":"10.1210\/clinem\/dgac071","article-title":"FGF23-Klotho Axis and Fractures in Patients Without and With Early CKD: A Case-Cohort Analysis of CARTaGENE","volume":"107","author":"Desbiens","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.23876\/j.krcp.18.0099","article-title":"Fracture risk in chronic kidney disease: A Korean population-based cohort study","volume":"38","author":"Kwon","year":"2019","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_64","first-page":"Cd006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"6","author":"Natale","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfad190","article-title":"Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients","volume":"39","author":"Ortiz","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/ndt\/gfae139","article-title":"Oral phosphate binders and incident osteoporotic fracture in patients on dialysis","volume":"40","author":"Kim","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/nep.14022","article-title":"Effects of phosphate binders on bone biomarkers and bone density in haemodialysis patients","volume":"27","author":"Udomkarnjananun","year":"2022","journal-title":"Nephrology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13363","article-title":"Serum phosphorus levels and fracture following renal transplantation","volume":"87","author":"Aleksova","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Evans, M., Methven, S., Gasparini, A., Barany, P., Birnie, K., MacNeill, S., May, M.T., Caskey, F.J., and Carrero, J.J. (2018). Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-20552-5"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfh829","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism","volume":"20","author":"Lien","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00774-024-01500-y","article-title":"Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: Meta-analysis of randomized trials","volume":"42","author":"Wakamatsu","year":"2024","journal-title":"J. Bone Miner. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Block, G.A., Chertow, G.M., Sullivan, J.T., Deng, H., Mather, O., Tomlin, H., and Serenko, M. (2019). An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213774"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wang, G., Liu, H., Wang, C., Ji, X., Gu, W., and Mu, Y. (2018). Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: A meta-analysis of randomized controlled trials and trial sequential analysis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-21397-8"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1210\/clinem\/dgac142","article-title":"Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis","volume":"107","author":"Komaba","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Eddington, H., Chinnadurai, R., Alderson, H., Ibrahim, S.T., Chrysochou, C., Green, D., Erekosima, I., Hutchison, A., Bubtana, A., and Hegarty, J. (2021). A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02312-2"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.ajkd.2023.10.007","article-title":"Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial","volume":"83","author":"Wang","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hung, K.C., Chang, J.F., Hsu, Y.H., Hsieh, C.Y., Wu, M.S., Wu, M.Y., Chiu, I.J., Syu, R.S., Wang, T.M., and Wu, C.C. (2020). Therapeutic Effect of Calcimimetics on Osteoclast-Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228712"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in Bone Quality after Treatment with Etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/ajt.12911","article-title":"A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism","volume":"14","author":"Evenepoel","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e13988","DOI":"10.1111\/ctr.13988","article-title":"Long-term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism","volume":"34","author":"Moreno","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20543581241283523","DOI":"10.1177\/20543581241283523","article-title":"The Efficacy and Safety of Bisphosphonate Therapy for Osteopenia\/Osteoporosis in Patients with Chronic Kidney Disease: A Systematic Review and Individual Patient-Level Meta-Analysis of Placebo-Controlled Randomized Trials","volume":"11","author":"Whitlock","year":"2024","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: A pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11657-020-00746-z","article-title":"Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: An open cohort multivariable and propensity score analysis from Funen, Denmark","volume":"15","author":"Ali","year":"2020","journal-title":"Arch. Osteoporos."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/prilozi-2018-0019","article-title":"Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease","volume":"39","author":"Aggarwal","year":"2018","journal-title":"Prilozi"},{"key":"ref_91","first-page":"510","article-title":"Treatment of reduced bone density with ibandronate in dialysis patients","volume":"21","author":"Bergner","year":"2008","journal-title":"J. Nephrol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s85.21.x","article-title":"Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis","volume":"63","author":"Torregrosa","year":"2003","journal-title":"Kidney Int. Suppl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/10815589231184215","article-title":"Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis","volume":"71","author":"Leng","year":"2023","journal-title":"J. Investig. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/ctr.12792","article-title":"Outcomes of bisphosphonate therapy in kidney transplant recipients: A systematic review and meta-analysis","volume":"30","author":"Francis","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_96","first-page":"Cd005015","article-title":"Interventions for preventing bone disease in kidney transplant recipients","volume":"10","author":"Palmer","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2004.12.007","article-title":"Interventions for preventing bone disease in kidney transplant recipients: A systematic review of randomized controlled trials","volume":"45","author":"Palmer","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2215\/CJN.0000000591","article-title":"Bisphosphonate Use after Kidney Transplantation Is Associated with Lower Fracture Risk","volume":"20","author":"Kahwaji","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.transproceed.2013.08.066","article-title":"Impact of vitamin D, bisphosphonate, and combination therapy on bone mineral density in kidney transplant patients","volume":"45","author":"Jeon","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yang, Y., Qiu, S., Deng, L., Tang, X., Li, X., Wei, Q., and Fu, P. (2018). Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: A systematic review and network meta-analysis. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1076-1"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"92335","DOI":"10.5500\/wjt.v14.i3.92335","article-title":"Impact of bisphosphonate treatment on bone mineral density after kidney transplant","volume":"14","author":"Georgopoulou","year":"2024","journal-title":"World J. Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic Acid and renal toxicity: Data from French adverse effect reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_104","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_111","first-page":"299","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur. J. Cancer Care"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08860220701260776","article-title":"The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women","volume":"29","author":"Yanik","year":"2007","journal-title":"Ren. Fail."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"ref_116","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years\u2019 effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause","volume":"4","author":"Burckhardt","year":"1994","journal-title":"Osteoporos. Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13730-014-0132-3","article-title":"Alendronate associated focal segmental glomerulosclerosis: A case report and review of the literature","volume":"4","author":"Garimella","year":"2015","journal-title":"CEN Case Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25170","article-title":"Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: A propensity score-matched cohort study","volume":"25","author":"Robinson","year":"2021","journal-title":"Health Technol. Assess."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10157-008-0078-x","article-title":"Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis","volume":"13","author":"Miura","year":"2009","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00198-007-0361-9","article-title":"Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate","volume":"18","author":"Pascual","year":"2007","journal-title":"Osteoporos. Int."},{"key":"ref_126","first-page":"91","article-title":"Alendronate-associated focal segmental glomerulosclerosis","volume":"2","author":"Prikis","year":"2009","journal-title":"NDT Plus"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00198-011-1836-2","article-title":"Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis","volume":"23","author":"Yilmaz","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_128","first-page":"Cd013424","article-title":"Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3\u20135D","volume":"7","author":"Hara","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e240159","DOI":"10.20945\/2359-4292-2024-0159","article-title":"Single zoledronic acid infusion as a cause of acute kidney impairment requiring dialysis in two patients with osteoporosis","volume":"68","author":"Marina","year":"2024","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","article-title":"Bisphosphonate use in chronic kidney disease: Association with adynamic bone disease in a bone histology series","volume":"29","author":"Amerling","year":"2010","journal-title":"Blood Purif."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kunizawa, K., Hiramatsu, R., Hoshino, J., Mizuno, H., Ozawa, Y., Sekine, A., Kawada, M., Sumida, K., Hasegawa, E., and Yamanouchi, M. (2020). Denosumab for dialysis patients with osteoporosis: A cohort study. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59143-8"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3904\/kjim.2023.292","article-title":"Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis","volume":"39","author":"Kim","year":"2024","journal-title":"Korean J. Intern. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis: A Target Trial Emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: A meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6218129","DOI":"10.1155\/2017\/6218129","article-title":"Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study","volume":"2017","author":"Takami","year":"2017","journal-title":"Int. J. Nephrol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","article-title":"Long-Term Effect of Denosumab on Bone Disease in Patients with CKD","volume":"18","author":"Iseri","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11657-019-0587-0","article-title":"Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: A systematic review and meta-analysis","volume":"14","author":"Thongprayoon","year":"2019","journal-title":"Arch. Osteoporos."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00223-024-01218-z","article-title":"Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group","volume":"115","author":"Fassio","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs. bisphosphonates in primary osteoporosis: A meta-analysis of comparative safety in randomized controlled trials","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos. Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for Infections During Treatment with Denosumab for Osteoporosis: A Systematic Review and Meta-analysis","volume":"105","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","first-page":"1235","article-title":"Safety of denosumab in patients with chronic kidney disease","volume":"32","year":"2021","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe Hypocalcemia with Denosumab Among Older Female Dialysis-Dependent Patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients with Low Bone Mass","volume":"100","author":"Chen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease","volume":"37","author":"Miller","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","article-title":"Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study","volume":"39","author":"Sato","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study","volume":"112","author":"Saito","year":"2023","journal-title":"Calcif. Tissue Int."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"ziaf096","DOI":"10.1093\/jbmrpl\/ziaf096","article-title":"Comparative analysis of romosozumab and denosumab treatment in hemodialysis patients with osteoporosis: A 12-mo observational study","volume":"9","author":"Teraguchi","year":"2025","journal-title":"JBMR Plus"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"ziaf049","DOI":"10.1093\/jbmrpl\/ziaf049","article-title":"Romosozumab for managing severe osteoporosis in patients undergoing kidney transplantation: A retrospective case series","volume":"9","author":"Tominaga","year":"2025","journal-title":"JBMR Plus"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men with Osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Vestergaard Kvist, A., Faruque, J., Vallejo-Yag\u00fce, E., Weiler, S., Winter, E.M., and Burden, A.M. (2021). Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J. Clin. Med., 10.","DOI":"10.3390\/jcm10081660"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: Post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00198-016-3858-2","article-title":"Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: A case report","volume":"28","author":"Wagner","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"254","DOI":"10.25259\/ijn_555_23","article-title":"Teriparatide Improves Bone Formation Markers and Bone Mineral Density in Adynamic Bone Disease Associated with Chronic Kidney Disease","volume":"34","author":"Jha","year":"2024","journal-title":"Indian. J. Nephrol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Oliveira, D., Garcia, S., Pereira, L., Magalh\u00e3es, J., Costa, L., Fraz\u00e3o, J., and Vaz, C. (2024). Effects of teriparatide on histomorphological features in a patient with an atypical femoral fracture and chronic kidney disease. Porto Biomed. J., 9.","DOI":"10.1097\/j.pbj.0000000000000253"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","article-title":"Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: A case report","volume":"65","author":"Palcu","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ckj\/sfv005","article-title":"Treatment of adynamic bone disease in a haemodialysis patient with teriparatide","volume":"8","author":"Giamalis","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5414\/CN110993","article-title":"Treatment of bone loss in CKD5D: Better survival in patients with non-high bone turnover","volume":"98","author":"Malluche","year":"2022","journal-title":"Clin. Nephrol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","article-title":"Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study","volume":"33","author":"Cejka","year":"2010","journal-title":"Kidney Blood Press. Res."},{"key":"ref_168","first-page":"451","article-title":"Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation","volume":"15","author":"Qiu","year":"2021","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","article-title":"Effect of teriparatide on early bone loss after kidney transplantation","volume":"8","author":"Cejka","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s11255-025-04383-8","article-title":"Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: A real-world experience","volume":"57","author":"Vetrano","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","article-title":"An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis","volume":"39","author":"Li","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Diaz Martinez, J.P., Aubry de Maraumont, T., Natty S\u00e1nchez, E., Camacho Cordero, L.M., and Yeh, E. (2025). Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0299673"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:22:13Z","timestamp":1763558533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":173,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228145"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228145","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}